Moderna Shares Decline Following Analyst Downgrade
Shares of Moderna, Inc. (NASDAQ:MRNA) fell after Wolfe Research adjusted its rating on the biotechnology company to Underperform on November 20, 2025. The stock was priced at $22.66 at the time of the downgrade. Currently, the stock is trading at $22.36, a decrease of approximately 7.55%, or $1.83 per share, for the day.
To support its financial strategy, Moderna secured a five-year loan of $1.5 billion from Ares Management. The company stated the financing is intended to help achieve up to 10% revenue growth in the upcoming year by providing resources for pipeline investment and operational expansion.
The stock exhibited significant volatility, with a daily trading range between $22.32 and $24.91. Over the last year, Moderna's stock has traded as high as $48.92 and reached a low of $22.32. The company's market capitalization stands at approximately $8.73 billion. Trading volume was active with 17.16 million shares exchanged.
Moderna, Inc. (MRNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.